COSCIENS Provides Strategic Update

COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”) today announced that the Company has made a strategic decision to cease funding its German subsidiaries, Aeterna ...
Endocrinology Advisor

Sogroya Approval Expanded to Include 3 Additional Pediatric Growth Disorders

FDA expands Sogroya approval for pediatric patients with Noonan syndrome, idiopathic short stature, and those born small for gestational age.

Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya

Novo Nordisk A/S (NYSE:NVO) is one of the best cheap stocks under $50 to buy right now. Novo Nordisk A/S (NYSE:NVO) announced ...

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya (R) (somapacitan-beco) injection 5 mg, 10 mg, or 15 mg, a ...
Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

The FDA has approved three new pediatric indications for somapacitan-beco, a once-weekly, long-acting growth hormone injection, according to a press release issued by Novo Nordisk.Somapacitan-beco ...
WJFW

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for ...

FDA Approves Novo Nordisk's Growth Disorder Treatment For New Populations

Novo Nordisk received approval from the Food and Drug Administration for three new indications of Sogroya, a growth hormone.
Medscape

Children Born SGA on Growth Hormone Therapy Show Impaired Glucose Metabolism

Children born small for gestational age (SGA) exhibited impaired glucose-insulin metabolism, similar to children with obesity, which worsened under growth hormone therapy. In contrast, children with ...
CBS News

Slowing U.S. population growth could reduce GDP by $100 billion in 2026, analysis finds

Slowing population growth could soon weigh on the U.S. economy, trimming an estimated $104 billion from the country's gross domestic product compared with what it would have been if population growth ...
The New York Times

Job Growth Was Overstated, New Data Shows

Annual revisions show that employers added far fewer jobs in 2024 and 2025 than previously estimated. Change in nonfarm employment since Jan. 2023. Note: Data is seasonally adjusted. Source: Bureau of ...
WBOC

Recognizing the Signs of Pediatric Growth Hormone Deficiency: How Early Recognition and Advocacy Helped One Family Find Answers

(Family Features) “Our concerns about Alex’s growth began around the age of 7,” said his mother, Diane Benke. Though Alex measured around the 50th percentile for weight, his height consistently ...
Healthline

Ngenla Overview: Side Effects, Uses, Dosage, and More

Ngenla (somatrogon-ghla) is a brand-name biologic medication prescribed to treat growth hormone deficiency (GHD) in some children, helping to increase their growth rate. The dosage of Ngenla is ...